This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takei, Y. Articles by Muramatsu, T. Search for Related Content PubMed PubMed Citation Articles by Takei, Y. Articles by Muramatsu, T.

Antisense Oligodeoxynucleotide Targeted to Midkine, a Heparin-binding Growth Factor, Suppresses Tumorigenicity of Mouse Rectal Carcinoma Cells¹

Departments of Biochemistry [Y. T., K. K., T. M.] and Internal Medicine [S. M.], Nagoya University School of Medicine, Nagoya 466-8550; Koken Bioscience Institute, Tokyo 169-0072 [H. I.]; and Department of Physiological Chemistry and Metabolism, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033 [K. N., S. K.], Japan

Midkine (MK), a heparin-binding growth factor, is overexpressed in a wide range of human carcinomas and is believed to contribute to tumorigenesis and tumor progression. To develop an antitumor reagent, we designed a phosphorothioate antisense oligodeoxynucleotide molecule based on the secondary structure of MK mRNA. The antisense MK at the dosage of 5 µM suppressed MK production by CMT-93 mouse rectal carcinoma cells after cationic liposome-mediated transfection, to 13% of that in control cultures. The growth of CMT-93 cells and their colony formation in soft agar were inhibited by the addition of the antisense MK, whereas the control reagent, the sense MK, showed no effects. On s.c. injection into nude mice, CMT-93 cells transfected with the antisense MK formed tumors much smaller than those by control cells. Finally, untreated CMT-93 cells were inoculated to nude mice, and 7 days later the antisense MK (50 µM) with atelocollagen was directly injected into the preformed tumor region to evaluate the curative effect; the injection was repeated at the interval of 2 weeks. During the period of 10–41 days after initiation of therapy, the rate of increase of tumor volume treated with the antisense MK was found to be about 4.2-fold lower than that seen after treatment with the sense MK. On this occasion, proliferation of tumor cells as estimated by 5-bromodeoxyuridine incorporation was strongly inhibited, whereas angiogenesis was less affected. These findings strongly suggested the usefulness of MK antisense oligodeoxynucleotide as a new reagent for cancer therapy.

This article has been cited by other articles:

				Y. Takei, T. Nemoto, P. Mu, T. Fujishima, T. Ishimoto, Y. Hayakawa, Y. Yuzawa, S. Matsuo, T. Muramatsu, and K. Kadomatsu In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency Mol. Cancer Ther., January 1, 2008; 7(1): 211 - 221. [Abstract] [Full Text] [PDF]

				S. Chen, G. Bu, Y. Takei, K. Sakamoto, S. Ikematsu, T. Muramatsu, and K. Kadomatsu Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells J. Cell Sci., November 15, 2007; 120(22): 4009 - 4015. [Abstract] [Full Text] [PDF]

				K. Inoh, H. Muramatsu, S. Torii, S. Ikematsu, M. Oda, H. Kumai, S. Sakuma, T. Inui, T. Kimura, and T. Muramatsu Doxorubicin-Conjugated Anti-Midkine Monoclonal Antibody as a Potential Anti-Tumor Drug Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 207 - 211. [Abstract] [Full Text] [PDF]

				T. Kosugi, Y. Yuzawa, W. Sato, H. Kawai, S. Matsuo, Y. Takei, T. Muramatsu, and K. Kadomatsu Growth Factor Midkine Is Involved in the Pathogenesis of Diabetic Nephropathy Am. J. Pathol., January 1, 2006; 168(1): 9 - 19. [Abstract] [Full Text] [PDF]

				K. Hayashi, H. Banno, K. Kadomatsu, Y. Takei, K. Komori, and T. Muramatsu Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2203 - H2209. [Abstract] [Full Text] [PDF]

				Y. Hirota, Y. Osuga, K. Koga, O. Yoshino, T. Hirata, M. Harada, C. Morimoto, T. Yano, O. Tsutsumi, S. Sakuma, et al. Possible implication of midkine in the development of endometriosis Hum. Reprod., April 1, 2005; 20(4): 1084 - 1089. [Abstract] [Full Text] [PDF]

				H. Kawai, W. Sato, Y. Yuzawa, T. Kosugi, S. Matsuo, Y. Takei, K. Kadomatsu, and T. Muramatsu Lack of the Growth Factor Midkine Enhances Survival against Cisplatin-Induced Renal Damage Am. J. Pathol., November 1, 2004; 165(5): 1603 - 1612. [Abstract] [Full Text] [PDF]

				Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics Cancer Res., May 15, 2004; 64(10): 3365 - 3370. [Abstract] [Full Text] [PDF]

				N. Suzuki, Y. Shibata, T. Urano, T. Murohara, T. Muramatsu, and K. Kadomatsu Proteasomal Degradation of the Nuclear Targeting Growth Factor Midkine J. Biol. Chem., April 23, 2004; 279(17): 17785 - 17791. [Abstract] [Full Text] [PDF]

				H. C. Kang, I.-J. Kim, J.-H. Park, Y. Shin, J.-L. Ku, M. S. Jung, B. C. Yoo, H. K. Kim, and J.-G. Park Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays Clin. Cancer Res., January 1, 2004; 10(1): 272 - 284. [Abstract] [Full Text] [PDF]

				P. Zou, K. Zou, H. Muramatsu, K. Ichihara-Tanaka, O. Habuchi, S. Ohtake, S. Ikematsu, S. Sakuma, and T. Muramatsu Glycosaminoglycan structures required for strong binding to midkine, a heparin-binding growth factor Glycobiology, January 1, 2003; 13(1): 35 - 42. [Abstract] [Full Text] [PDF]

				Y. Shibata, T. Muramatsu, M. Hirai, T. Inui, T. Kimura, H. Saito, L. M. McCormick, G. Bu, and K. Kadomatsu Nuclear Targeting by the Growth Factor Midkine Mol. Cell. Biol., October 1, 2002; 22(19): 6788 - 6796. [Abstract] [Full Text] [PDF]

				Y. Takei, K. Kadomatsu, H. Itoh, W. Sato, K. Nakazawa, S. Kubota, and T. Muramatsu 5'-,3'-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine. ITS DESIGN AND APPLICATION FOR CANCER THERAPY J. Biol. Chem., June 21, 2002; 277(26): 23800 - 23806. [Abstract] [Full Text] [PDF]